ArticleThe American journal of pathology2000
Modulation of human colon tumor-stromal interactions by the endothelin system.
Article in The American journal of pathology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 78 citations in OpenAlex.
- The Tetraspanin Tspan8 Associates with Endothelin Converting Enzyme ECE1 and Regulates Its Activity.Cancers · 2023Article
- Endothelin-1 axes in the framework of predictive, preventive and personalised (3P) medicine.The EPMA journal · 2021Review
- Modulation of the Endothelin System in Colorectal Cancer Liver Metastasis: Influence of Epigenetic Mechanisms?Frontiers in pharmacology · 2020Article
- Endothelin Promotes Colorectal Tumorigenesis by Activating YAP/TAZ.Cancer research · 2017Article
- Endothelin 1 in cancer: biological implications and therapeutic opportunities.Nature reviews. Cancer · 2013Review
- Endothelin-1 enriched tumor phenotype predicts breast cancer recurrence.ISRN oncology · 2013Article
- Role of the endothelin axis and its antagonists in the treatment of cancer.British journal of pharmacology · 2011Review
- Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.Neoplasia (New York, N.Y.) · 2011Article
- Stromal endothelin B receptor-deficiency inhibits breast cancer growth and metastasis.Molecular cancer therapeutics · 2009Article
- Endothelin-3 stimulates survival of goblet cells in organotypic cultures of fetal human colonic epithelium.American journal of physiology. Gastrointestinal and liver physiology · 2008Article
- Isoforms of endothelin-converting enzyme-1 (ECE-1) have opposing effects on prostate cancer cell invasion.British journal of cancer · 2008Article
- Transcription analysis in the MeLiM swine model identifies RACK1 as a potential marker of malignancy for human melanocytic proliferation.Molecular cancer · 2008Article
- Endothelin receptor A blockade enhances taxane effects in prostate cancer.Neoplasia (New York, N.Y.) · 2006Article
- Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.Current oncology reports · 2006Article
- Article
- Endothelin receptors as novel targets in tumor therapy.Journal of translational medicine · 2004Article
- Structure, evolutionary conservation, and functions of angiotensin- and endothelin-converting enzymes.International review of cytology · 2004Review
- Immunohistochemical localization of endothelin-converting enzyme-1 in neuroendocrine tumors and normal human tissue.The Kaohsiung journal of medical sciences · 2003Article
- Endothelin-receptor antagonists are proapoptotic and antiproliferative in human colon cancer cells.British journal of cancer · 2003Article
- Endothelin-1: a multifunctional molecule in cancer.British journal of cancer · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor neovascularization is considered to be a critical step in the development of a malignant tumor. Endothelin (ET)-1 is a powerful vasoconstrictor and mitogenic peptide that is produced by many cancer cell lines. The cellular distribution of the ET components was evaluated in human colon tumors and compared to normal colon. There was more of the ET components (preproET-1, endothelin-converting enzyme-1, and ETA and ETB receptors) in adenomas and adenocarcinomas than in the normal colon. There was overproduction of preproET-1 and endothelin-converting enzyme-1 in carcinoma cells and stromal vessels, suggesting that they are a local source of ET-1. ETA receptors were present in stromal myofibroblasts of neoplastic tissue, and there were large amounts of ETB receptors in the endothelium and myofibroblasts. There was also a redistribution of alpha-smooth muscle actin-positive cells in the vascular structures of tumors. An experimental rat model of induced colon cancer treated for 30 days with bosentan, a mixed antagonist of both ET receptors, confirmed the morphological changes observed during the tumor vascularization. Our data suggest that ET-1 and its receptor play a role in colon cancer progression, with ET-1 functioning as a negative modulator of the stromal response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.